tbuckley/cabot-search huggingface dataset:
The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer
Authors: Yohei Kubota, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Kentaro Sawada, Yoshiaki Nakamura, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Genichiro Ishii, Takeshi Kuwata, Kohei Shitara
Journal: Clinical Cancer Research (2020)

Abstract Purpose: We evaluated the association between molecular subtypes of advanced gastric cancer (AGC) and the efficacy of standard chemotherapy or immune checkpoint inhibitors. Experimental Design: Patients with AGC who received systemic chemotherapy from October 2015 to July 2018 with available molecular features were analyzed. We investigated the efficacy of standard first- (fluoropyrimidine + platinum ± trastuzumab) and second-line (taxanes ± ramucirumab) chemotherapy, and subsequent anti–PD-1 therapy in patients with four molecular subtypes: MMR-D (mismatch repair deficient), EBV+, HER2+, and all negative. Results: 410 patients were analyzed: MMR-D 5.9%, EBV+ 4.1%, HER2+ 13.7%, and all negative 76.3%. In 285 patients who received standard first-line chemotherapy, the median progression-free survival (PFS) times were 4.2, 6.0, 7.5, and 7.6 months and the objective response rates (ORR) were 31%, 62%, 60%, and 49% in MMR-D, EBV+, HER2+, and all-negative subtypes, respectively. Multivariate analysis showed shorter PFS in MMR-D versus all-negative patients [HR, 1.97; 95% CIs, 1.09–3.53; P = 0.022]. In second-line setting, there were no significant differences in efficacy. In 110 patients who received anti–PD-1 therapy, median PFS times were 13.0, 3.7, 1.6, and 1.9 months and the ORRs were 58%, 33%, 7%, and 13%, respectively. Twelve patients with MMR-D received subsequent anti–PD-1 therapy and showed longer PFS compared with that in 10 (83%) patients who received earlier-line chemotherapy. Conclusions: MMR-D might result in shorter PFS with first-line chemotherapy for AGC. Subsequent anti–PD-1 therapy achieved higher ORR and longer PFS than prior chemotherapy in most patients with MMR-D, supporting the earlier use of immune checkpoint inhibitors.
Substitution of cisplatin for etoposide in 2 of 3 induction cycles of CAV/IE with subsequent irinotecan and vincristine for relapse in adults with Ewing sarcoma (ES) and primitive neuroectodermal tumor (PNET).
Authors: Daniel A. Rushing, Obiageli Ezewuiro, Sandra S. Staehler, Kristin Potter, Luis Rojas, Stephanie Glacy Wagner
Journal: Journal of Clinical Oncology (2012)

9571 Background: Treatment for adults with cyclophosphamide, doxorubicin and vincristine alternating with ifosfamide and etoposide (CAV/IE) for ES/PNET is based on the success reported in children however the same treatment in adults is less effective. 50% of relapsed disease is expected to occur in the lungs with median survival of 12.5 months (mo) after relapse. Since Cisplatin is used for relapse, we initially substituted cisplatin for etoposide in courses # 2 and # 3 of IE for 2 patients (pts) who were not responding to IE as determined by serial CT scanning and then used it for all pts. Relapsed pts were treated with irinotecan + vincristine (IRI-V) for at least 2 cycles as salvage therapy. We report the effect of cisplatin on influencing the relapse pattern and the effect of IRI-V on survival for pts after relapse Methods: A retrospective chart review of 19 consecutive adult pts (July 2004 to June 2011), with newly diagnosed ES /PNET were treated with CAV/IE as per H. Grier NEJM 2003 and modified as a 14 day cycle. Cisplatin 20 mg/m2 I.V. q d X4 was substituted for etoposide for courses # 2 and 3 of IE and combined with ifosfamide as above (IC) followed by surgery or RT. For pts with relapse Irinotecan was given I.V. 20mg/m2 days 1-5 &amp; 8-12 + vcr I.V. 2mg days 1 &amp; 8 q21 days for 2 or more cycles. Repeat treatment with CAV, IE or IC was also utilized for relapse. We evaluated the toxicities, the pattern of relapse and the survival after relapse with these treatments Results: Grade IV hematologic toxicity occurred in 11 of 19 pts treated with CAV vs. 7of 19 pts treated with IE vs. 7 of 19 pts treated with IC and 1 of 11 pts treated with IRI-V but 3 of those 11 pts had Grade IV diarrhea. Median survival was 44.8+ mo for 10 pts with non- metastatic and 23 mo for 9 pts with metastatic disease respectively. More importantly median survival from the time of relapse was 22.5+ mo, (range 12.7 to 31+ mo). 11 pts relapsed: 2 pts only in bone, 9 pts Local only, 0 pts had distant lung recurrence Conclusions: Cisplatin appears to markedly alter the relapse pattern in adults with ES/PNET and Irinotecan +vcr appears to prolong survival in relapsed pts previously treated with cisplatin.
Low levels of radiofrequency electromagnetic fields and cancer cell proliferation in vivo.
Authors: Boris Pasche, Jacquelyn W. Zimmerman, Hugo Jimenez, Michael J. Pennison, Ivan Brezovich, Nengjun Yi, Niels Kuster, Frederico Costa, Alexandre Barbault
Journal: Journal of Clinical Oncology (2013)

e15049 Background: The incidence of hepatocellular carcinoma (HCC) is increasing but five-year survival remains dismal. Intrabuccal administration of amplitude-modulated radiofrequency electromagnetic fields (RF EMF) is a novel, non-invasive treatment modality resulting in whole body absorption of very low levels of RF EMF. Recent studies show that this approach elicits radiological responses in patients with HCC and breast cancer (J Exp Clin Cancer Res, 2009, 28:51; Br J Cancer, 2011, 105:640). Using an in vitro exposure system replicating the levels of exposure achieved in humans, we have shown that HCC cells and breast cancer cells are growth inhibited by HCC-specific and breast cancer-specific frequencies, respectively. Additionally, RF EMF exposure causes modulation of gene expression and disruption of the mitotic spindle (Br J Cancer 2012, 106:307). Methods: HCC cells were exposed to radiofrequency electromagnetic fields modulated at specific frequencies previously identified in HCC patients. MicroRNA arrays compared exposed and control groups of HCC cells. HCC cells were injected subcutaneously in NOD SCID mice. Following palpable tumor establishment, mice were exposed to HCC-specific RF EMF at a specific absorption rate of 0.4 W/kg and euthanized following excessive tumor burden. Results: We identified increased levels of miRNAs targeting proteins belonging to the PI3K pathway, specifically IP3/DAG signaling and intracellular calcium release, a pathway frequently disrupted in HCC and breast cancer. While HCC xenografts grew in control mice, we observed significant tumor shrinkage in mice exposed to HCC-specific modulation frequencies and residual xenograft tumor cells were infiltrated with fibrous tissue and showed significantly decreased proliferation and increased apoptosis. There was no evidence of altered cell proliferation or fibrosis in other organs. Conclusions: These findings are the first in vivo evidence of the efficacy of RF EMF in HCC and uncover a novel mechanism that targets cancer cell growth at specific modulation frequencies, by means of changes in PI3K signaling and release of intracellular calcium.
BPI20-008: Pilot Testing of InheRET™, an Online Tool to Facilitate NCCN Guideline®-Compliant Referrals for Cancer Genetic Counseling and Increase Access to Care
Authors: Amanda M. Cook, David F. Keren, Lynn McCain, Lee F. Schroeder, Kara Milliron, Sofia Merajver, Diane Harper, Philip Zazove, Janice Farrehi, Susan Ernst, Jasmine Parvaz
Journal: Journal of the National Comprehensive Cancer Network (2020)

"BPI20-008: Pilot Testing of InheRET™, an Online Tool to Facilitate NCCN Guideline®-Compliant Referrals for Cancer Genetic Counseling and Increase Access to Care" published on 20 Mar 2020 by National Comprehensive Cancer Network.
THE SIGNIFICANCE OF AN INSIGNIFICANT PARAVALVULAR LEAK
Authors: Linnea Lebaron, John W. Prather, Mandar Jagtap, Mehul Patel, Thomas Flautt, Likhitesh Jaikumar, Alison Spangler, Dakshin Gangadharamurthy, Theodore Richards
Journal: Journal of the American College of Cardiology (2020)
CLINICAL AND ECHOCARDIOGRAPHIC PARAMETERS IN PEDIATRIC PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY: RELATIONSHIP TO LV GLOBAL LONGITUDINAL STRAIN
Authors: Jared Klein, Alaa Alashi, Laurence Max Svensson, Rukmini Komarlu, Elizabeth Saarel, Peter Aziz, Hani Najm, Harry Lever, Kenneth Zahka, Milind Y. Desai
Journal: Journal of the American College of Cardiology (2020)
PREDICTORS OF READMISSION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: ANALYSIS OF NATIONAL READMISSION DATABASE
Authors: Dixitha Anugula, Nagarjuna Reddy Gujjula, Raviteja Guddeti, Ryan Walters, Dennis Esterbrooks, Arun Kanmanthareddy
Journal: Journal of the American College of Cardiology (2020)
BODY MASS INDEX AND HEMODYNAMICS IN THE ADULT FONTAN POPULATION
Authors: Vidhushei Yogeswaran, Christopher Anigwe, Sarah Blissett, Anika Aggarwal, Anita Moon Grady, Elyse Foster, Vaikom S. Mahadevan, Ian Stewart Harris, Anushree Agarwal
Journal: Journal of the American College of Cardiology (2020)
CARDIOPROTECTIVE EFFECT OF CANNABIDIOL IN A NON ISCHEMIC MODEL OF HEART FAILURE
Authors: Omar Lozano, Gerardo García-Rivas, Martín Ramos, Eduardo Vázquez-Garza, Héctor Chapoy-Villanueva, Néstor Rubio, Víctor Treviño, James Bolton, Guillermo Torre-Amione
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF MORPHINE USE ON MORTALITY IN STEMI PATIENTS TREATED WITH PRIMARY PCI
Authors: Istvan Hizoh, Dominika Domokos, Gyongyver Banhegyi, Laszlo Major, Istvan Ferenc Edes, David Becker, Zoltan Ruzsa, Bela Merkely
Journal: Journal of the American College of Cardiology (2020)
Quality assurance of radiotherapy in the Japan Clinical Oncology Group trial 0211 concerning concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: The individual case review
Authors: M. Oguchi, Y. Kagami, S. Ishikura, K. Nihei, Y. Ito, M. Yamaguchi, K. Tobinai, I. Wasada, T. Hotta, K. Oshimi
Journal: Journal of Clinical Oncology (2006)

17561 Background: It is challenging to conduct a high quality multi-institutional clinical trial for localized nasal NK/T-cell lymphoma due to the anatomical complexity and its rarity. The purpose of this study was to evaluate the compliance with protocol guidelines in concurrent chemoradiotherapy for this disease among radiotherapy institutions participating in a multi-center phase I/II JCOG trial 0211. Methods: The treatment consisted of radiotherapy 50 Gy and 3 cycles of DeVIC chemotherapy [carboplatin, etoposide, ifosfamide, dexamethasone] (Yamaguchi M, et al.: Proc ASH, 2005). CT-based three-dimensional treatment planning was required to cover adequately target volumes and to minimize doses to organs at risk such as the eyes, the brain stem and the spinal cord. Patient data were sent to the review center after the treatments have been finalized. The following parameters were evaluated by the quality assurance review board: treatment records and charts; simulation films; portal images; prescribed dose; dose fractionation and overall treatment time; dose distributions; and dose to risk organs. Results: At the time of phase I analysis, 10 patients were enrolled in this study. In 2 of 10 cases, process of treatment planning was not available. There was no protocol violation. Major deviations were identified as follows: Delineation of clinical target volume (&lt; 2 cm from the edge of the gross tumor volume at any direction), 2/10; dose distribution (not covered by 90%-115% isodose line), 1/10; and dose to optic chiasm (&gt;40 Gy), 1/10. All cases were compliant in prescribed dose, dose fractionation, and overall treatment time. In the last 4 of 10 cases, attending radiation oncologists at the participating institutions were contacted by the radiation oncology study chair and they discussed the treatment planning just after patient enrollment. These 4 cases were all protocol compliant compared to 6 cases with 4 major deviations. Conclusions: Individual case review is essential in a multi-center clinical trial to keep enrolled cases protocol compliant and minimize inter-institutional variations. We expect that our quality assurance program will maintain the quality of the JCOG trial 0211. No significant financial relationships to disclose.
Use of Indocyanine Green for Intraoperative Ureteral Identification in Nonurologic Surgery
Authors: Pratik Kanabur, Christy Chai, Jennifer Taylor
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Comparative outcomes of splenectomy and rituximab-based chemotherapy in elderly patients with splenic marginal zone lymphoma.
Authors: Adam J. Olszewski
Journal: Journal of Clinical Oncology (2013)

8549 Background: Despite advances in diagnosis and therapy, over 50% of patients with splenic marginal zone lymphoma (SMZL) undergo splenectomy. The objective of this retrospective study was to compare outcomes in SMZL patients undergoing surgery or rituximab-containing chemoimmunotherapy (RCIT) based on the Surveillance, Epidemiology, and End Results-Medicare linked database. Methods: Records of 521 SMZL patients diagnosed between 2000 and 2007 were extracted, excluding cases with incomplete Medicare coverage. Two treatment arms were defined by receipt of RCIT or splenectomy within 2 years of diagnosis. Factors confounding treatment selection or prognosis were balanced in both arms using a propensity score. The primary endpoint was lymphoma-related death, estimated using competing risk models, with overall survival (OS) and toxicities as secondary endpoints. Results: Of the 341 eligible patients (median age, 77 years), 67 (20%) were untreated, while 169 (50%) underwent splenectomy and 97 (28%) chemotherapy (64% single-agent rituximab) at median 1.4 months from diagnosis. Stage IE, treatment in a teaching hospital and good performance status were associated with a preference for splenectomy. There was no evidence of significantly different risk of lymphoma-related death after treatment with RCIT rather than surgery (hazard ratio, HR, 1.10, 95%CI 0.56-2.18, P=0.78). There was an excess of early mortality after splenectomy (7% within 90 days) but more later events with RCIT (OS at 3 years 69% vs. 67%, respectively). More patients required chemotherapy after surgery (38%) than vice versa (14%, P&lt;0.001). Nursing home admissions were more common after splenectomy (22%, P=0.03). There were more inpatient hospitalizations after multidrug RCIT (P=0.003), but not after rituximab alone (P=0.65). Conclusions: Although SMZL is considered indolent, most elderly patients required treatment soon after diagnosis in this population-based study. Survival outcomes were similar after either RCIT or splenectomy. Complications of surgery or combination chemotherapy are significant, suggesting rituximab alone as a more suitable option in elderly patients.
WEARABLE TECHNOLOGY AND ITS ROLE IN DETECTION OF ABNORMAL HEART RHYTHMS
Authors: Vijay Pratap Singh, Swaiman Singh, Alexis Okoh, Harleen Bhatti, Guneive Kaur Mangat, Harpran Singh Deol, Gurvijay Singh Bains, Affan Farooq, Gurdarshan Singh Sandhu, Sunny Singh
Journal: Journal of the American College of Cardiology (2020)
RETAINED TARGET LESION LIPID CONTENT AFTER STENTING AND THE RISK OF SUBSEQUENT TARGET LESION FAILURE
Authors: Adnan Kassier, Ryan Madder, Takashi Kubo, Yasushi Ino, Takeyoshi Kameyama, Kosei Terada, Stacie Vanoosterhout, Abby Mulder, Michael McNamara, Mohamad Kenaan, Soroush Samani, Jessica Parker, Richard McNamara, Takashi Akasaka
Journal: Journal of the American College of Cardiology (2020)
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial
Authors: Vianney Tricou, Xavier Sáez-Llorens, Delia Yu, Luis Rivera, José Jimeno, Ana Cecilia Villarreal, Epiphany Dato, Onix Saldaña de Suman, Nathali Montenegro, Rodrigo DeAntonio, Sonia Mazara, Maria Vargas, Debbie Mendoza, Martina Rauscher, Manja Brose, Inge Lefevre, Suely Tuboi, Astrid Borkowski, Derek Wallace
Journal: The Lancet (2020)
Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
Journal: Journal of Clinical Oncology (1997)

PURPOSE Adjuvant tamoxifen has been shown to reduce relapse and mortality among node-positive post-menopausal breast cancer patients. The value of adding chemotherapy to tamoxifen is controversial. PATIENTS AND METHODS Between July 1986 and April 1993, 1,266 postmenopausal breast cancer patients with node-positive disease were randomly assigned to receive one of four adjuvant therapy regimens: (A) tamoxifen alone for 5 years; (B) tamoxifen plus three courses of early cyclophosphamide, methotrexate, and fluorouracil (CMF) on months 1, 2, and 3; (C) tamoxifen plus delayed single courses of CMF on months 9, 12, and 15; (D) tamoxifen plus early and delayed CMF on months 1, 2, 3, 9, 12, and 15. The two-by-two factorial design allowed two direct comparisons: early CMF (B and D) versus no early CMF (A and C), and delayed CMF (C and D) versus no delayed CMF (A and B). Estrogen receptor (ER) status was known for all patients and was used to stratify the randomization. A total of 1, 212 patients (96%) were eligible and assessable. The median follow-up duration was 60 months. RESULTS The results of the two-by-two factorial comparisons were as follows: (1) early CMF added to tamoxifen significantly improved 5-year disease-free survival (DFS; 64% v 57%; hazards ratio [HR], 0.79; 95% confidence interval [CI], 0.66 to 0.95; P = .01); and (2) delayed CMF added to tamoxifen did not improve DFS (5-year DFS, 61% v 60%; HR, 0.97; 95% CI, 0.81 to 1.17; P = .77). For patients with ER-positive tumors, the addition of CMF, either early or delayed or both, reduced the relative risk of relapse by 22% to 36%. In contrast, for patients with ER-negative tumors, tamoxifen with delayed CMF was associated with a nonsignificant increased risk of relapse (HR, 1.27; 95% CI, 0.92 to 1.76; P = .15). CONCLUSION Postmenopausal patients with node-positive breast cancer should be offered combination chemotherapy in addition to tamoxifen. Tamoxifen should not be initiated before CMF, as this might be detrimental, especially for patients with ER-negative tumors.
Real-world treatment profile for patients with tuberous sclerosis complex related angiomyolipoma: A U.S. Healthcare Claims Database study.
Authors: Peter Sun, Zhimei Liu, Michael Kohrman, John Bissler
Journal: Journal of Clinical Oncology (2012)

e15096 Background: Angiomyolipoma (AML) is a common benign neoplasm associated with tuberous sclerosis complex (TSC). The objective of this study is to examine the treatment profile for patients with TSC related AML in a real world setting. Methods: A retrospective cohort study was performed using a large US commercial healthcare claims database. Patients with a TSC claim (ICD-9CM: 759.5X) and an AML claim (ICD-9CM: 223.0X) between 2000 and 2009 and with continuous 12-month health plan enrollment after their first AML claim were included into the study. The utilization rates of thirty two medication groups, eight procedure categories, five service places and fifteen provider types were assessed and ranked respectively for the year before first AML claim and the year after the first AML claim. Repeated measures analysis was used to compare these utilization rates between the last pre-AML year and the first post-AML year. Results: The study included 180 patients with a mean age of 28.2 years on their first AML claims, and 67.8% were females. During the first post-AML year, the top five medication groups were central nervous system medications (59.4%), anti-infective agents (50.6%), hormones &amp; synthetic substance (22.8%), cardiovascular agents (18.9%), and autonomic drugs (17.8%); the most commonly used outpatient procedures were evaluation &amp; management procedures (99.4%), anesthesia procedures (99.4%), surgical procedures (72.8%), radiology procedures (96.1%), and medicine procedures (100.0%). More patients consume the following care in the first post-AML year than in the last pre-AML year: anti-infective agents (50.6% vs. 35.0%, p&lt;0.05), surgical procedures (72.8% vs. 60.6%, p&lt;0.05), emergency rooms care (31.1% vs. 18.3%, p&lt;0.05), urologists’ care (38.9% vs. 16.1%, p&lt;0.05), nephrologists’ care (22.3% vs. 11.7%, p&lt;0.05). Conclusions: In a real world setting and among TSC patients with AML, treatment profile changed after the first observed AML diagnosis. Further research is needed to examine the impact of these changes on economic and clinical outcomes of healthcare for patients with TSC related AML.
Abstract 19046: The Role of the SYNTAX Score in Predicting Clinical Outcome in Diabetic Patients After Percutaneous Coronary Intervention and Coronary Artery Bypass Graft: A FREEDOM Trial Sub-analysis
Authors: Rodrigo B Esper, Expedito E Ribeiro, Whady Hueb, Michael Domanski, Taye Hamza, Sandi Siami, Michael E Farkouh, Valentin Fuster
Journal: Circulation (2017)

Background: Diabetes mellitus (DM) associates with complex coronary artery disease (CAD), what in turn translates into increased morbidity from cardiovascular disease. The SYNTAX Score (SS) is an a...
CLINICAL OUTCOMES OF SURVIVORS OF OUT-OF-HOSPITAL CARDIAC ARREST WITHOUT ST ELEVATION RECEIVING PERCUTANEOUS CORONARY INTERVENTION
Authors: Beni Rai Verma, Vikram Sharma, Manpreet Kaur, Agam Bansal, Shameer Khubber, Vardhmaan Jain, Shashank Shekhar, Kamalpreet Dhaliwal, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)